Longevity & AgingPrimeC Combo Drug Shows Early Promise Against Alzheimer's Biomarkers
NeuroSense has released early findings from a small Phase 2 trial testing PrimeC — an oral pill combining the antibiotic ciprofloxacin and the anti-inflammatory celecoxib — in Alzheimer's disease patients. The study enrolled eight participants, with three completing 12 months of follow-up. Blood and spinal fluid analyses showed changes in key Alzheimer's-related proteins, including tau, amyloid-beta, and TDP-43, moving in directions consistent with the drug's proposed mechanism. Markers of inflammation and oxidative stress also shifted favorably. No serious side effects were reported. The company stresses these findings are exploratory and the sample size is too small to draw firm conclusions, but plans to use this data to design a larger, more definitive trial.
